---
title: "Eli Lilly Stock (LLY) Hits All-Time High as Post-Earnings Rally Accelerates"
type: "News"
locale: "zh-CN"
url: "https://longbridge.com/zh-CN/news/265393605.md"
description: "Eli Lilly's stock (LLY) reached an all-time high of $966.55 on Nov. 10, following a strong third-quarter earnings report that exceeded expectations. The stock rose 4.8% after reporting EPS of $7.02 and revenue of $17.60 billion, driven by sales of its weight-loss drug Zepbound. Additionally, a deal with the Trump administration to reduce costs for Medicare patients contributed to the rally. LLY has gained 21% in the last 30 days and holds a consensus Strong Buy rating from analysts, with a price target of $985.39."
datetime: "2025-11-11T20:07:54.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/265393605.md)
  - [en](https://longbridge.com/en/news/265393605.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/265393605.md)
---

> 支持的语言: [English](https://longbridge.com/en/news/265393605.md) | [繁體中文](https://longbridge.com/zh-HK/news/265393605.md)


# Eli Lilly Stock (LLY) Hits All-Time High as Post-Earnings Rally Accelerates

The stock of U.S. pharmaceutical giant Eli Lilly (LLY) has hit an all-time high as the rally that began after the company's recent third-quarter financial results accelerates.

### Meet Your ETF AI Analyst

-   Discover how TipRanks' _ETF_ AI Analyst can help you make smarter investment decisions
-   Explore ETFs TipRanks' users love and see what insights the **_ETF_ AI Analyst** reveals about the ones you follow.

LLY stock rose 4.8% on Nov. 10 to close at a record high of $966.55. The previous record close of $960.02 occurred on Aug. 30, 2024. In afternoon trading on Nov. 11, Eli Lilly's stock was up another 2.43% and hit an intraday all-time high of $999.95.

The rise in LLY stock is a sharp reversal from earlier this year when the share price languished over concerns about demand for its weight-loss drugs and price controls on pharmaceuticals that could be imposed by U.S. President Donald Trump. Even with the current rally, Eli Lilly's stock is only up 18% over the past 12 months.

## **Catalysts**

Eli Lilly's stock has been rallying due to two catalysts that have emerged over the past month. The first was the company's third-quarter print. Eli Lilly reported earnings per share (EPS) of $7.02, which was far ahead of the $5.69 expected on Wall Street. Revenue of $17.60 billion surpassed consensus forecasts of $16.01 billion. Strong sales of the weight-loss drug Zepbound drove the financial results.

The other catalyst has been the deal Eli Lilly reached with the Trump administration to provide Medicare and Medicaid coverage for the company's weight-loss drugs. Under terms of the deal, Medicare patients will pay only $50 per month for all approved uses of injectable and oral obesity medications. The drugs currently cost consumers as much as $1,000 a month.

LLY stock has now gained 21% in the last 30 days.

## **Is LLY Stock a Buy?**

The stock of Eli Lilly has a consensus Strong Buy rating among 20 Wall Street analysts. That rating is based on 17 Buy and three Hold recommendations issued in the last three months. The average LLY price target of $985.39 implies 0.53% downside from current levels.

### 相关股票

- [Eli Lilly (LLY.US)](https://longbridge.com/zh-CN/quote/LLY.US.md)

## 相关资讯与研究

- [Eli Lilly Stock (LLY) Surges as FDA Approves Weight-Loss Pill](https://longbridge.com/zh-CN/news/281437997.md)
- [Traders Buy High Volume of Eli Lilly and Company Call Options (NYSE:LLY)](https://longbridge.com/zh-CN/news/281412176.md)
- [Lilly to acquire Centessa Pharmaceuticals to advance treatments for sleep-wake disorders | LLY Stock News](https://longbridge.com/zh-CN/news/281171668.md)
- [Wegovy vs. Foundayo: Novo Nordisk's "Record-Breaking" Run Meets the Eli Lilly (LLY) Challenge](https://longbridge.com/zh-CN/news/281503903.md)
- [Insig AI Plans Growth Drive and Eyes Nasdaq Dual Listing](https://longbridge.com/zh-CN/news/281311983.md)